Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA clears Hansen's visualisation device

This article was originally published in Clinica

Executive Summary

Hansen Medical's CoHesion 3D visualisation module has gained US FDA 510(k) clearance for use in complex electrophysiology (EP) mapping procedures. It is designed to help surgeons to "instinctively" navigate a catheter during the diagnostic phase of a complex cardiac arrhythmia procedure, the Mountain View, California firm said. The CoHesion module has a software interface between Hansen's Sensei robotic catheter system and the EnSite system – 3D mapping software developed by St Jude Medical. EnSite's cardiac chamber model with anatomic labelling is imported into the Sensei system's main navigation window, allowing physicians to see the location of the catheter within the heart in three dimensions. The CoHesion module was launched in the EU earlier this year.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT042380

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel